Neumora's Pipeline Credibility Rests on Two Readouts Due Within Weeks

Neumora Therapeutics (NMRA) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with the central question being whether the clinical-stage biotech can demonstrate progress on its pipeline—particularly the highly anticipated KOASTAL-2 and -3 navacaprant data readout—while managing its cash runway through Q3 2027. With the stock trading at $1.83, down sharply from recent levels, investors face a critical juncture: can positive clinical catalysts reverse the downward momentum, or will continued losses and technical weakness persist?

Part 1: Earnings Preview

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for central nervous system disorders, including major depressive disorder, Alzheimer's disease agitation, and schizophrenia. The company leverages its proprietary Neuroscience Cloud platform to integrate data and machine learning for novel target identification and therapy development.

Neumora is expected to report first-quarter 2026 results on May 11, 2026, with analysts projecting a loss of $0.25 per share on no revenue. The company most recently reported Q4 2025 earnings of -$0.30 per share, beating the consensus estimate of -$0.32. Year-over-year, the expected Q1 2026 loss of -$0.25 represents a 24% improvement compared to the -$0.33 loss reported in Q2 2025 (same quarter last year), reflecting reduced R&D and G&A expenses as the company focuses resources on key pipeline programs.

Three narrative themes dominate this earnings story:

KOASTAL-2 and -3 Navacaprant Readout Timing: The joint topline data readout for the Phase 2 KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder is expected in Q2 2026, making this the most critical near-term catalyst. Both studies enrolled more than 400 patients each, and the company has indicated pre-specified analyses will include data from over 450 patients enrolled after study optimizations in early 2025. Success here could validate Neumora's kappa opioid receptor antagonist approach and significantly de-risk the pipeline.

Pipeline Momentum Beyond Navacaprant: Neumora reported Phase 1b results for NMRA-511 in Alzheimer's disease agitation showing what the company described as an "unsurpassed effect size" with favorable tolerability and no somnolence or sedation. Data from a multiple ascending dose (MAD) expansion cohort evaluating higher doses is expected in H2 2026, with a Phase 2 study anticipated to begin in Q1 2027. Additionally, NMRA-898 (M4 positive allosteric modulator) for schizophrenia is in Phase 1 with data expected in H2 2026, and NMRA-215 (NLRP3 inhibitor) for obesity is advancing toward clinic entry in Q1 2027. This breadth demonstrates the company's ability to progress multiple programs despite resource constraints.

Cash Runway and Financial Discipline: With $147.1 million in cash and cash equivalents as of March 31, 2026, Neumora expects to fund operations into Q3 2027. The company reduced R&D expenses to $38.6 million in Q1 2026 (down from $52.2 million in Q1 2025) and G&A expenses to $14.3 million (down from $18.8 million), demonstrating disciplined capital allocation. However, the limited runway means the company will likely need to raise additional capital or secure partnerships before key Phase 2 readouts, creating potential dilution risk for shareholders.

Analysts remain cautiously optimistic heading into the release. Guggenheim maintains a buy rating with a $14 price target, while Needham & Company also rates the stock a buy with an $8 target. Leerink Partners initiated coverage with an outperform rating and $8 target in January 2026. The consensus view emphasizes the importance of the upcoming KOASTAL data as a potential inflection point, with analysts noting that positive results could significantly re-rate the stock given its current valuation. However, some caution that the company's cash position and need for future financing create execution risk, particularly if clinical timelines slip or results disappoint.

Part 2: Historical Earnings Performance

Neumora has demonstrated a mixed earnings track record over the past four quarters, with two beats and two misses against consensus estimates. In Q2 2025, the company reported a loss of -$0.33 per share, beating the -$0.38 estimate by 13.16%—the strongest outperformance in the recent period. However, both Q3 2025 and Q4 2025 saw modest misses, with the company reporting -$0.35 versus estimates of -$0.34 in each quarter (-2.94% miss for both). Most recently, Q1 2026 (reported March 30, 2026) delivered a beat, with actual EPS of -$0.30 versus the -$0.32 estimate (+6.25% surprise).

The pattern suggests Neumora has improved its ability to manage expenses and deliver results closer to or better than expectations in recent quarters. The Q1 2026 beat was driven by lower-than-anticipated R&D and G&A costs, reflecting the company's focus on disciplined capital allocation as it navigates toward key clinical catalysts. The trend of narrowing losses—from -$0.33 in Q2 2025 to -$0.30 in Q1 2026—aligns with management's stated goal of extending the cash runway while maintaining momentum across multiple pipeline programs. However, the two consecutive misses in Q3 and Q4 2025 indicate that expense management remains challenging, and investors should watch whether the company can sustain the positive momentum demonstrated in the most recent quarter.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Neumora typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Neumora's post-earnings price action has been highly volatile, with an average absolute Day 0 move of 7.45% and Day +1 move of 2.28%. The most dramatic reaction came on November 12, 2024, when the stock plunged 17.08% on Day 0 and continued lower by 4.73% on Day +1, reflecting significant disappointment with that quarter's results. More recently, the March 30, 2026 earnings release triggered a sharp 17.17% decline on Day 0, though the stock recovered modestly with a 1.04% gain on Day +1, suggesting initial overreaction.

The historical pattern shows directional unpredictability—some quarters see initial gains followed by reversals (May 7, 2024: +4.92% Day 0, -3.98% Day +1), while others show consistent downward pressure across both days. The average Day 0 range of 12.08% indicates substantial intraday volatility regardless of direction. For the upcoming May 11 release, investors should prepare for a potential 7-8% move based on historical averages, with the possibility of significantly larger swings if clinical updates or cash runway guidance surprise in either direction. The recent March 2026 earnings reaction—a sharp initial decline followed by modest recovery—may provide a template for how the market could respond to this quarter's results, particularly given the proximity to the anticipated KOASTAL data readout.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 19.51% (±$0.36) for the May 15, 2026 expiration, which is significantly higher than the historical average Day 0 move of 7.45% and even exceeds the average Day 0 range of 12.08%. This elevated implied volatility of 224.99% suggests options traders are anticipating a larger-than-typical reaction, likely reflecting heightened uncertainty around the KOASTAL-2 and -3 data timing and potential pipeline updates that could be disclosed during the earnings call.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Neumora, with the stock carrying an average recommendation of 4.00 (Buy) and a mean price target of $9.14—representing 399% upside from the current price of $1.83. The consensus is supported by 5 Strong Buy ratings and 2 Moderate Buy ratings, offset by 2 Hold ratings and 1 Strong Sell rating among the 10 analysts covering the stock.

The sentiment trend is classified as unchanged over the past month, indicating analysts have maintained their conviction despite recent stock weakness. The price target range is wide, spanning from a low of $3.00 to a high of $18.00, reflecting significant disagreement about the company's risk-reward profile. The high target of $18.00 implies nearly 10x upside and likely assumes successful KOASTAL data and subsequent regulatory progress, while the $3.00 low target suggests more conservative assumptions around clinical execution and financing needs.

The bullish consensus appears anchored on the belief that positive KOASTAL-2 and -3 results could serve as a major catalyst, with several analysts highlighting the potential for navacaprant to address a large unmet need in major depressive disorder. The breadth of the pipeline—with NMRA-511, NMRA-898, and NMRA-215 all advancing—provides additional optionality that supports the buy thesis. However, the presence of hold and sell ratings reflects concerns about execution risk, cash runway constraints, and the binary nature of upcoming clinical readouts. The unchanged sentiment suggests analysts are in a wait-and-see mode ahead of the KOASTAL data, with the potential for significant rating and target revisions depending on those results.

Part 4: Technical Picture

Neumora enters earnings in a deteriorating technical position, with the Barchart Technical Opinion shifting from 32% Buy last week to 24% Sell currently, though this represents an improvement from the 8% Sell signal seen a month ago. The stock is trading at $1.83, below all major moving averages: the 5-day ($2.14), 10-day ($2.23), 20-day ($2.20), 50-day ($2.46), 100-day ($2.38), and 200-day ($2.20). This universal underperformance versus moving averages signals broad-based technical weakness across all timeframes.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, with the stock failing to hold support at key short-duration moving averages
• Medium-term (50% Buy): Moderate buy signal suggests some intermediate-term support remains, possibly reflecting expectations for the upcoming KOASTAL data catalyst
• Long-term (50% Sell): Moderate sell signal reflects persistent weakness in the longer-term trend, consistent with the stock's decline from higher levels earlier in the year

Trend Characteristics: The Weak Average trend environment suggests indecisive price action with limited directional conviction, creating an uncertain backdrop heading into earnings.

The technical setup is cautionary heading into the May 11 earnings release. The stock's position below all moving averages, combined with the shift to a sell signal in the past week, indicates sellers have maintained control despite the stock trading near recent lows. The 50-day moving average at $2.46 represents 34% overhead resistance, while the 200-day at $2.20 marks a critical long-term level the stock has failed to reclaim. The conflicting medium-term buy signal against short- and long-term sell signals suggests the market is divided on whether the upcoming KOASTAL data can reverse the downtrend. Given the weak trend characteristics and universal underperformance versus moving averages, the technical picture suggests limited support if earnings or pipeline updates disappoint, while a strong positive surprise would need to clear the $2.20-$2.46 resistance zone to signal a meaningful trend reversal.